205 related articles for article (PubMed ID: 17616807)
1. PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
Lei H; Hemminki K; Johansson R; Altieri A; Enquist K; Henriksson R; Lenner P; Försti A
Breast Cancer Res Treat; 2008 May; 109(1):165-75. PubMed ID: 17616807
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
[TBL] [Abstract][Full Text] [Related]
3. Markers of the uPA system and common prognostic factors in breast cancer.
Minisini AM; Fabbro D; Di Loreto C; Pestrin M; Russo S; Cardellino GG; Andreetta C; Damante G; Puglisi F
Am J Clin Pathol; 2007 Jul; 128(1):112-7. PubMed ID: 17580278
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.
Błasiak J; Smolarz B
Acta Biochim Pol; 2000; 47(1):191-9. PubMed ID: 10961693
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M
Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.
Eroglu A; Ulu A; Cam R; Akar N
J BUON; 2006; 11(4):481-4. PubMed ID: 17309181
[TBL] [Abstract][Full Text] [Related]
7. Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival.
Zhang X; Shu XO; Cai Q; Ruan Z; Gao YT; Zheng W
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6037-42. PubMed ID: 17062678
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer.
Foekens JA; Ries C; Look MP; Gippner-Steppert C; Klijn JG; Jochum M
Cancer Res; 2003 Jan; 63(2):337-41. PubMed ID: 12543785
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast.
Yagmurdur MC; Atac FB; Tutar NU; Verdi H; Isiklar I; Ozdemir BH; Ozbek N; Karakayali H; Haberal M
Int Surg; 2008; 93(3):163-8. PubMed ID: 18828272
[TBL] [Abstract][Full Text] [Related]
11. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
12. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ; Duggan C
Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphism of the plasminogen activator inhibitor-1 is associated with an increased risk of endometrial cancer.
Su CK; Yeh KT; Yeh CB; Wang PH; Ho ES; Chou MC; Liu KC; Yang SF; Yi YC
J Surg Oncol; 2011 Dec; 104(7):755-9. PubMed ID: 21761413
[TBL] [Abstract][Full Text] [Related]
14. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
15. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
16. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer.
Palmirotta R; Ferroni P; Savonarola A; Martini F; Ciatti F; Laudisi A; Sini V; Del Monte G; Guadagni F; Roselli M
Thromb Res; 2009 Sep; 124(4):403-8. PubMed ID: 19351570
[TBL] [Abstract][Full Text] [Related]
18. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
[TBL] [Abstract][Full Text] [Related]
19. Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers.
Duffy MJ
Biochem Soc Trans; 2002 Apr; 30(2):207-10. PubMed ID: 12023852
[TBL] [Abstract][Full Text] [Related]
20. PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells.
Alvarez-Millán JJ; Bocos C; Ferrín V; Lucas AR; Ruibal A; Schneider J
Oncology; 2002; 62(3):286-90. PubMed ID: 12065877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]